"HEALTH, ADDICTION TREATMENT, AND THE CRIMINAL JUSTICE SYSTEM"
M. Douglas Anglin, Ph.D. is Director of the University of
California at Los Angeles Drug Abuse Research Center and Professor in Residence of Medical Psychology in the Department of Psychiatry and Biobehavioral Sciences, at the University of California. He has devoted over
twenty-five years to research in the area of drug use research with a special focus on drug epidemiology, evaluation of treatment, and the social and individual consequences related to drug use. Dr. Anglin has
written over 150 articles for policymaking, practitioner, and other professional journals. He has also served as a member of several advisory and task force panels on drug use and drug user treatment.
Steven Belenko, Ph.D. is a Senior Research Associate at The National Center on Addiction and Substance Abuse at Columbia University. Previous research and management positions were at the New York City Criminal Justice Agency, the Mayor's Criminal Justice Coordinating Council, Mathematica Policy Research, and the Vera Institute of Justice. He has directed a number of research projects on the impact of drug offenders on the criminal justice system, substance abuse treatment for criminal offenders, crack cocaine, and drug courts.
David Farabee, Ph.D. has served as lead analyst for criminal justice research at the Texas Commission on Alcohol and Drug Abuse (1992-1995), Assistant Professor of Psychiatry, and Research Scientist at the University of Kentucky Center on Drug and Alcohol Research (1995-1997). He is presently study director of a five-year evaluation of the California Substance Abuse Treatment Facility (funded by the California Department of Corrections) and Principal Investigator for a multisite evaluation of three residential substance abuse treatment facilities for youth offenders (funded by the California Youth Authority). He has published in the areas of substance misuse, crime, and offender treatment.
Kevin Knight, Ph.D. is a Research Scientist at the Institute of Behavioral Research (IBR) at Texas Christian University. His research, reported in over 30 publications, centers on evaluating corrections-based treatment effectiveness. His recent work emphasizes the assessment of treatment process and the development of evaluation systems for correctional settings. Since joining the IBR faculty in 1991, he has been centrally involved in the design and implementation of several longitudinal evaluations for treatment of probation and prison populations. As a result, he has worked closely with criminal justice agencies and data systems at national and regional levels. Dr. Knight also has served as an advisor to a variety of organizations which address drug abuse and related policy issues.
Douglas S. Lipton, Ph.D. is a Senior Research Fellow at National
Development and Research Institutes, Inc. (NDRI) in New York City. From 1988 to 1992, he was Director of Research at NDRI (then Narcotic and Drug Research, Inc.). Dr. Lipton is currently conducting a NIDA-funded
comprehensive meta-analysis of all correctional treatment studies from 1968-1996, measuring substance abuse and mental health within the Deaf population, and is conducting a national evaluation of residential
substance abuse treatment in correctional settings (with a cooperative agreement grant from the National Institute of Justice). He has evaluated drug abuse control and treatment programs around the world for the UN,
consults regularly with HM Prison Service in GB and the CSC in Ottawa, and served as expert consultant to the Partnership for a Drug Free America since its origin. He has taught at several universities and
co-authored or edited 6 books and almost 200 publications.
Frank S. Pearson, Ph.D. is Project Director of the National Institute on
Drug Abuse funded meta-analytical review of evaluation research on correctional treatment programs, reported from 1968 to the present. He is also Project Director on a project funded by the National Institute of
Justice (NIJ) to provide a national evaluation of the Residential Substance Abuse Treatment (RSAT) programs being funded by the Corrections Program Office. Previously, while an Associate Research Professor at
Rutgers University from 1983 to 1994, he conducted a variety of research projects, including the following: Co-Principal Investigator and Study Director of a four-year project to conduct a research evaluation of the
State of New Jersey's Intensive Supervision Program; Co-Principal Investigator and Study Director of a research project examining urinalysis-based deterrence of drug use by convicted felons while they are under
supervision in the community; Co-Principal Investigator on a research project to analyze national survey data, collected by the U. S. Census Bureau, focusing on the relation of school-system efforts at control and
discipline to rates of criminal victimization.
D. Dwayne Simpson, Ph.D. is Director of the Institute of Behavioral
Research (IBR) and the S.B. Sells Professor of Psychology at Texas Christian University. His research on drug addiction and treatment effectiveness (reported in over 200 publications) has included several
large-scale longitudinal evaluations in national and regional multisite projects. His recent work emphasizes assessment of patient functioning and service delivery process, and how these factors influence treatment
engagement and retention rates, stages of recovery, and long-term outcomes of addicts. It includes the development of cognitive and behavioral interventions that can enhance patient services and improvements in
program management, both in community-based and correctional treatment settings.
Ken Winters, Ph.D. is the Director of the Center for Adolescent
Substance Abuse and an Associate Professor in the Department of Psychiatry at the University of Minnesota. Dr. Winters and his colleagues have developed a widely-used assessment system for the evaluation and
referral of adolescents suspected of problems due to drug abuse. His research interests include the assessment and treatment of adolescent drug abuse, the role of attention deficit/hyperactivity disorder and conduct
disorder as a risk for early drug involvement, and the prevalence and etiology of the spectrum of addictive disorders. Support for Dr. Winters' research is primarily provided by NIDA.